BioSpace News Archive

Many biopharma companies raised funds in 2022, but not enough to reach their next milestone. Investors have been constricting investments, so companies needing additional funding require a larger toolbox.

Hemispherian AS, a Norwegian preclinical pharmaceutical company focused on small molecule cancer therapeutics targeting the DNA damage response, is delighted to announce the closure of the first tranche of its series A1 financing round.

Hoffmann-La Roche Limited is pleased to announce that on November 14, 2022, Health Canada has authorized POLIVY® in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone for the treatment of adult patients with previously untreated large B-cell lymphoma, including diffuse large B-cell lymphoma not otherwise specified, high grade B-cell lymphoma, Epstein-Barr virus-positive DLBCL NOS, and T-cell/histiocyte rich LBCL.

With the FDA Modernization Act’s passage earlier this year, drug developers have the opportunity to forgo animal models in preclinical development for the first time in history.

Shanghai Junshi Biosciences Co., Ltd, a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the company has submitted a marketing authorization application to the United Kingdom’s Medicines and Healthcare products Regulatory Agency for toripalimab.

Kane Biotech Inc. announced its third quarter 2022 financial results.

Medicure Inc. reported its results from operations for the quarter ended September 30, 2022.

Mabwell, an innovative biopharmaceutical company with the layout of whole industry chain, announced that its clinical trial application for 9MW3011 Injection used in patients with polycythemia vera was formally approved by the United States Food and Drug Administration.

A clinical study to explore the influence of BR1 on rheumatoid arthritis conducted by Professor Gregory J. Tsai from China Medical University Hospital in Taiwan was published at a meeting of the American Association of Immunologist, a top medical society in the US.

Revive Therapeutics Ltd. announced that it will submit the Type C meeting request package to the US FDA by mid-December 2022, which will outline the overall development plan and Pre-Dose selection data supporting the latest revised endpoints for the Company’s Phase 3 clinical trial to evaluate the safety and efficacy of Bucillamine, an oral drug with anti-inflammatory and antiviral properties, in patients with mild to moderate COVID-19.